A Non-Viral Vector for Targeting Gene Therapy to Motoneurons in the CNS

被引:13
作者
Miana-Mena, Francisco J. [1 ,2 ]
Munoz, Maria J. [3 ]
Roux, Sylvie [4 ]
Ciriza, Jesus [1 ,2 ]
Zaragoza, Pilar [1 ,2 ]
Brulet, Philippe [4 ]
Osta, Rosario [1 ,2 ]
机构
[1] Lab Genet Bioquim, ES-50013 Zaragoza, Spain
[2] Fac Vet Zaragoza, Grp Sanguineos, ES-50013 Zaragoza, Spain
[3] Fac Vet Zaragoza, Dept Farmacol & Fisiol, Zaragoza, Spain
[4] Inst Pasteur, Unite Embryol Mol, Paris, France
关键词
Gene therapy; Naked DNA; Tetanus toxin; C fragment; Pattern expression; Retrograde transport; Transsynaptic transport;
D O I
10.1159/000080050
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Gene therapy vectors that can be targeted to motoneuronal cells are required in the field of neurodegenerative diseases. We propose the use of the atoxic fragment C of tetanus toxin (TTC) as biological activity carrier to the motoneurons. Naked DNA encoding beta-galactosidase-TTC hybrid protein was used to transfect muscle cells in vivo, resulting in a selective gene transfer of the enzymatic activity to the CNS. In the muscle, level expression of beta-galactosidase was readily detectable 24 h after injection, reaching a maximum after 4 days and gradually decreasing thereafter. Labelling in the hypoglossal motoneurons and motor cortex was observed from 4 days after injection. In this paper, we show that TTC works as an enzymatic activity carrier to the CNS when muscle cells are transfected in vivo. We have also shown that the presence of TTC does not have any influence on the expression of the transfected gene. Both these results warrant further studies of TTC as a means of treating motoneuron diseases in the field of gene therapy. Copyright (C) 2004 S. Karger AG, Basel
引用
收藏
页码:101 / 108
页数:8
相关论文
共 50 条
  • [41] Lipid-based Non-viral Vector: Promising Approach for Gene Delivery
    Panday, Anupama
    Dixena, Bhupendra
    Jain, Nishant
    Jain, Akhlesh Kumar
    CURRENT PHARMACEUTICAL DESIGN, 2025, 31 (07) : 521 - 539
  • [42] Impact of DNA Vector Topology on Non-Viral Gene Therapeutic Safety and Efficacy
    Sum, Chi H.
    Wettig, Shawn
    Slavcev, Roderick A.
    CURRENT GENE THERAPY, 2014, 14 (04) : 309 - 329
  • [43] Materials for non-viral gene delivery
    Segura, T
    Shea, LD
    ANNUAL REVIEW OF MATERIALS RESEARCH, 2001, 31 : 25 - 46
  • [44] Non-Viral Gene Delivery Methods
    Wang, Weiwei
    Li, Wenzhong
    Ma, Nan
    Steinhoff, Gustav
    CURRENT PHARMACEUTICAL BIOTECHNOLOGY, 2013, 14 (01) : 46 - 60
  • [45] Editorial: Non-viral vectors for gene therapy/nucleic acid delivery
    Poddar, Arpita
    Banerjee, Rajkumar
    Shukla, Ravi
    FRONTIERS IN BIOENGINEERING AND BIOTECHNOLOGY, 2023, 11
  • [46] Novel cationic pentablock copolymers as non-viral vectors for gene therapy
    Agarwal, A
    Unfer, R
    Mallapragada, SK
    JOURNAL OF CONTROLLED RELEASE, 2005, 103 (01) : 245 - 258
  • [47] Non-viral ocular gene therapy: Potential ocular therapeutic avenues
    Bloquel, C.
    Bourges, J. L.
    Touchard, E.
    Berdugo, M.
    BenEzra, D.
    Behar-Cohen, F.
    ADVANCED DRUG DELIVERY REVIEWS, 2006, 58 (11) : 1224 - 1242
  • [48] Peptide-mediated DNA condensation for non-viral gene therapy
    Saccardo, Paolo
    Villaverde, Antonio
    Gonzalez-Montalban, Nuria
    BIOTECHNOLOGY ADVANCES, 2009, 27 (04) : 432 - 438
  • [49] Multifunctional cationic polyurethanes designed for non-viral cancer gene therapy
    Cheng, Jian
    Tang, Xin
    Zhao, Jie
    Shi, Ting
    Zhao, Peng
    Lin, Chao
    ACTA BIOMATERIALIA, 2016, 30 : 155 - 167
  • [50] Low molecular weight oligochitosans for non-viral retinal gene therapy
    Puras, G.
    Zarate, J.
    Aceves, M.
    Murua, A.
    Diaz-Tahoces, Ariadna
    Aviles-Triguero, M.
    Fernandez, E.
    Pedraz, J. L.
    EUROPEAN JOURNAL OF PHARMACEUTICS AND BIOPHARMACEUTICS, 2013, 83 (02) : 131 - 140